One of the core issues in managing advanced NSCLC is second line chemotherapy, which was established as improving survival several years ago. This video presentation provides a brief summary of the work that led to the common use of chemotherapy in previously treated patients. Most typically, this is taxotere (docetaxel) or alimta (pemetrexed), and this presentation describes why we focus most commonly on these chemo agents.
Importantly, another second line treatment option is the oral EGFR inhibitor tarceva (erlotinib), a targeted therapy and not standard chemotherapy. The work leading to the approval of tarceva as a second or third line treatment for advanced NSCLC will be covered in a separate presentation.
As with other presentations, below you'll find links to the figures as well as the transcript for this program.
Although the fact that this program is sponsored by Mr. Alec Brindle is mentioned in the program itself, I wanted give special thanks to Mr. Brindle for his support, financial and personal, in bringing OncTalk and then GRACE from an idea to a real mechanism for helping the cancer community.
We truly need additional support to continue these activities. I and the other people working to deliver great content here are extremely gratified by the kind comments of appreciation that people provide, but we can't pay the people working on these programs with that. Please make a donation to help support these programs.